For the quarter ending 2025-09-30, PMN had $10,889,046 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -11,580,127 | -17,464,932 |
| Share-based compensation expense | 197,147 | 457,310 |
| Prepaid expenses and other current assets | 1,059,605 | -620,912 |
| Accounts payable | 1,431,306 | 1,042,716 |
| Accrued liabilities | 955,654 | 6,562,946 |
| Net cash used in operating activities | -10,055,625 | -8,781,048 |
| Proceeds from issuance of common shares pursuant to atm offering, net of issuance costs | 708,468 | - |
| Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs | 697,658 | - |
| Proceeds from issuance of common shares, pre-funded warrants, and accompanying warrants from july 26, 2024 pipe, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | 8,391,027 | - |
| Proceeds from issuance of common shares, pre-funded warrants, and accompanying warrants from july 26, 2024 pipe, net of issuance costs-July282025Exercise Of Discounted Warrants And Pipe Offering | 11,144,468 | - |
| Proceeds from exercise of pre-funded warrants | 3,050 | - |
| Net cash provided by financing activities | 20,944,671 | - |
| Net increase in cash | 10,889,046 | -8,781,048 |
| Cash and cash equivalents at beginning of period | 13,291,167 | - |
| Cash and cash equivalents at end of period | 15,399,165 | - |
ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. (PMN)